AU729886B2 - Method of inhibiting cancer growth - Google Patents

Method of inhibiting cancer growth Download PDF

Info

Publication number
AU729886B2
AU729886B2 AU59104/98A AU5910498A AU729886B2 AU 729886 B2 AU729886 B2 AU 729886B2 AU 59104/98 A AU59104/98 A AU 59104/98A AU 5910498 A AU5910498 A AU 5910498A AU 729886 B2 AU729886 B2 AU 729886B2
Authority
AU
Australia
Prior art keywords
cmt
dimethylamino
tetracycline
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU59104/98A
Other languages
English (en)
Other versions
AU5910498A (en
Inventor
Norman L. Block
Lorne M. Golub
Hsi-Ming Lee
Balakrishna L. Lokeshwar
Thomas F. Mcnamara
Nungavaram S. Ramamurthy
Marie G. Selzer
Sanford Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Research Foundation of the State University of New York
Original Assignee
University of Miami
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Research Foundation of the State University of New York filed Critical University of Miami
Publication of AU5910498A publication Critical patent/AU5910498A/en
Application granted granted Critical
Publication of AU729886B2 publication Critical patent/AU729886B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU59104/98A 1997-01-15 1998-01-15 Method of inhibiting cancer growth Ceased AU729886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/783655 1997-01-15
US08/783,655 US5837696A (en) 1997-01-15 1997-01-15 Method of inhibiting cancer growth
PCT/US1998/000332 WO1998031224A1 (en) 1997-01-15 1998-01-15 Method of inhibiting cancer growth

Publications (2)

Publication Number Publication Date
AU5910498A AU5910498A (en) 1998-08-07
AU729886B2 true AU729886B2 (en) 2001-02-15

Family

ID=25130005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59104/98A Ceased AU729886B2 (en) 1997-01-15 1998-01-15 Method of inhibiting cancer growth

Country Status (11)

Country Link
US (2) US5837696A (enExample)
EP (1) EP0971585B1 (enExample)
JP (1) JP4428727B2 (enExample)
KR (1) KR20000070212A (enExample)
AT (1) ATE321452T1 (enExample)
AU (1) AU729886B2 (enExample)
CA (1) CA2277865C (enExample)
DE (1) DE69834024T2 (enExample)
ES (1) ES2262221T3 (enExample)
PT (1) PT971585E (enExample)
WO (1) WO1998031224A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429204B1 (en) 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
CA2316972C (en) * 1997-12-19 2009-02-24 New York University Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
JP2002533404A (ja) * 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6984619B1 (en) * 1999-03-19 2006-01-10 Arch Development Corporation Method for protection against tumor metastasis formation
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP2332546A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
RU2300380C2 (ru) * 2001-10-05 2007-06-10 Тетрадженекс Фармасьютикалс, Инк. Производные тетрациклина и способы их применения
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EA201000491A1 (ru) 2002-03-08 2010-08-30 Паратек Фармасьютикалс, Инк. Аминометилзамещенные тетрациклиновые соединения
WO2003079984A2 (en) 2002-03-21 2003-10-02 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
KR20050005466A (ko) * 2002-05-06 2005-01-13 콜라제넥스 파마슈티칼스, 인크 점막염 및 진균 감염을 동시에 치료하는 방법
JP2005533766A (ja) * 2002-05-20 2005-11-10 コッラジェネックス ファーマシューチカルス インコーポレイテッド アレルギー反応の治療方法
EA012136B1 (ru) 2002-07-12 2009-08-28 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
WO2004038000A2 (en) * 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
JP5586123B2 (ja) * 2003-04-07 2014-09-10 スパーナス ファーマシューティカルズ インコーポレイテッド テトラサイクリンの1日1回製剤
EP1648859B1 (en) 2003-07-09 2013-02-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド 9−アミノメチルテトラサイクリン化合物のプロドラッグ
EP2332904A3 (en) 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2284152A3 (en) 2004-10-25 2011-10-05 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2006272698B2 (en) * 2005-07-21 2012-11-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
ES2548261T3 (es) 2006-12-21 2015-10-15 Paratek Pharmaceuticals, Inc. Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
AU2007338681B2 (en) 2006-12-21 2013-09-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2008134048A2 (en) * 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
CN101784517A (zh) * 2007-07-06 2010-07-21 帕拉特克药品公司 合成取代的四环素化合物的方法
TW202021946A (zh) * 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
ES2655911T3 (es) 2008-08-08 2018-02-22 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina sustituidos con C7-fluoro
ES2627772T3 (es) 2009-05-08 2017-07-31 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina
JP5944825B2 (ja) 2009-08-28 2016-07-05 テトラフェース ファーマシューティカルズ,インコーポレイテッド テトラサイクリン化合物
US20120329761A1 (en) * 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
JP5820462B2 (ja) 2010-03-31 2015-11-24 テトラフェース ファーマシューティカルズ,インコーポレイテッド 多環式テトラサイクリン化合物
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
ES2978198T3 (es) 2016-10-19 2024-09-06 Tetraphase Pharmaceuticals Inc Formas cristalinas de eravaciclina
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012717A2 (en) * 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5321017A (en) * 1989-12-04 1994-06-14 The Research Foundation Of State University Of New York Composition comprising fluriprofen and effectively non-antibacterial tetracycline to reduce bone loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5563130A (en) * 1994-12-13 1996-10-08 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5321017A (en) * 1989-12-04 1994-06-14 The Research Foundation Of State University Of New York Composition comprising fluriprofen and effectively non-antibacterial tetracycline to reduce bone loss
WO1992012717A2 (en) * 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis

Also Published As

Publication number Publication date
ES2262221T3 (es) 2006-11-16
EP0971585A1 (en) 2000-01-19
ATE321452T1 (de) 2006-04-15
CA2277865A1 (en) 1998-07-23
US5837696A (en) 1998-11-17
DE69834024T2 (de) 2006-12-07
US6100248A (en) 2000-08-08
AU5910498A (en) 1998-08-07
JP4428727B2 (ja) 2010-03-10
KR20000070212A (ko) 2000-11-25
WO1998031224A1 (en) 1998-07-23
JP2001508794A (ja) 2001-07-03
EP0971585B1 (en) 2006-03-29
EP0971585A4 (en) 2001-01-24
CA2277865C (en) 2009-06-02
DE69834024D1 (de) 2006-05-18
PT971585E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
AU729886B2 (en) Method of inhibiting cancer growth
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
Seftor et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
US6429204B1 (en) Method of inhibiting cancer growth
AU755871B2 (en) Combination of bisphosphonate and tetracycline
Fan et al. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy
EP1119362B1 (en) Use of tetracycline derivatives to enhance interleukin-10 production
Ryan et al. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis
US20190091244A1 (en) Methods of treating acne
CA2031368C (en) Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline
Zervos et al. Matrix Metalloproteinase Inhibition Attenuates Human Pancreatic Cancer Growthin Vitroand Decreases Mortality and Tumorigenesisin Vivo
CA2440472C (en) Methods of treating acne
MXPA99006554A (en) Method of inhibiting cancer growth
Seftor et al. Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis
Schneider et al. Tetracyclines inhibit intracellular muscle proteolysis in vitro
CN101420960A (zh) 使用非抗菌四环素制剂治疗主动脉狭窄的方法
NZ522733A (en) Non-antibacterial tetracycline as anti-fungal agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)